Tilray's Stock Is Down 45% This Year, and Here's Why It Could Still Go Lower

Tilray is down 45% year to date in 2026, and the article argues the stock could fall further as Trulieve uplists to the NYSE, giving investors a more direct way to access U.S. marijuana exposure. Tilray continues to post operating losses, with losses in each of the past four quarters, and its diversification into beverages has not offset weak fundamentals. The key catalyst is a shift in investor preference away from Tilray as a proxy for U.S. cannabis upside.

Analysis

The competitive implication is not just that Tilray loses a marketing edge; it loses the narrative monopoly that supported its scarcity premium. Once a cleaner U.S.-exposed vehicle can trade on a major exchange, passive and generalist capital has less reason to own a structurally weaker balance sheet and slower-growth proxy for the same macro theme. That matters because cannabis equities trade more on perceived optionality than near-term cash flow, so even a small reduction in narrative scarcity can cause disproportionate multiple compression.

The second-order effect is that capital is likely to rotate toward the names with the most credible U.S. pathway, while integrated “story stocks” that lean on beverages or non-U.S. geographies may face renewed skepticism. If the U.S. market remains the only real long-duration profit pool, then investors will increasingly discriminate between companies with direct U.S. operating exposure and those selling a diluted future thesis. That creates a broader winner/loser split inside the group: better-capitalized MSOs and exchange-listed U.S. operators gain relative appeal, while Canada-centric names get boxed into a lower-quality consumer-growth bucket.

The risk setup for TLRY is asymmetric over the next 1-3 months because there is no obvious catalyst to reassert a premium multiple, while the market now has a visible alternative. A reversal would require either a sharper-than-expected improvement in fundamentals or a policy event that disproportionately benefits non-U.S. operators, neither of which looks imminent. The contrarian take is that the move may still be underdone if the re-rating process is driven by benchmarking flows; once investors can compare U.S. cannabis exposure directly against TLRY, the stock could continue to bleed simply from relative underownership rather than new bad news.

Key Decisions for Investors

• Short TLRY on rallies over the next 2-6 weeks; use a tight risk cap because the trade is mostly multiple compression rather than fundamentals. Favor entries after any retail-driven bounce, with downside target of 15-25% if the sector rotates toward U.S.-listed exposure.
• Long the cleaner U.S. cannabis proxy versus TLRY in a pair trade over 1-3 months. The clean expression is long the most institutionally accessible U.S. operator or exchange-listed beneficiary and short TLRY; the spread should benefit if capital rotates toward direct U.S. exposure.
• Buy TLRY put spreads 2-4 months out to monetize continued narrative decay while limiting premium paid. Structure for a moderate move lower rather than a collapse, since the stock can remain highly volatile on policy headlines.
• Avoid chasing cannabis beta broadly until the market proves that rescheduled-policy enthusiasm converts into actual earnings power. The sector remains a headline trade first, fundamental trade second; wait for either improved cash burn or a better capital markets entry point.
• If TLRY rallies on sector sympathy, use that strength to reduce exposure rather than add. The risk/reward is unfavorable because the upside case depends on a broad legalization path, while the downside can reprice immediately as investors prefer direct U.S. exposure.